|
| 38009241 | A phase 2 open-label extension study of prekallikrein inhibition with donidalorsen for hereditary angioedema. | Allergy | 2024 |
| 37852604 | Hereditary angioedema in older adults: Understanding the patient perspective. | Ann Allergy Asthma Immunol | 2024 |
| 36411000 | Hereditary Angioedema During Pregnancy: Considerations in Management. | Immunol Allergy Clin North Am | 2023 |
| 38082409 | Patient outcomes associated with subcutaneous C1INH prophylaxis for hereditary angioedema: a retrospective analysis. | Allergy Asthma Clin Immunol | 2023 |
| 37746795 | Evaluation of patient-reported outcome measures for on-demand treatment of hereditary angioedema attacks and design of KONFIDENT, a phase 3 trial of sebetralstat. | Clin Transl Allergy | 2023 |
| 37393005 | Managing Chronic Urticaria and Angioedema: Novel Insights. | J Allergy Clin Immunol Pract | 2023 |
| 37328263 | Healthcare utilization of patients with hereditary angioedema treated with lanadelumab and subcutaneous C1-inhibitor concentrate. | Allergy Asthma Proc | 2023 |
| 37028510 | Long-term lanadelumab treatment improves health-related quality of life in patients with hereditary angioedema. | Ann Allergy Asthma Immunol | 2023 |
| 36720386 | Hereditary Angioedema With Normal C1 Inhibitor: US Survey of Prevalence and Provider Practice Patterns. | J Allergy Clin Immunol Pract | 2023 |
| 36610760 | Urticaria and Angioedema: Understanding Complex Pathomechanisms to Facilitate Patient Communication, Disease Management, and Future Treatment. | J Allergy Clin Immunol Pract | 2023 |
| 36872446 | Hereditary Angioedema: Impact of COVID-19 pandemic stress upon disease related morbidity and well-being. | Allergy Asthma Proc | 2023 |
| 36774155 | An investigational oral plasma kallikrein inhibitor for on-demand treatment of hereditary angioedema: a two-part, randomised, double-blind, placebo-controlled, crossover phase 2 trial. | Lancet | 2023 |
| 36463068 | Update on skin diseases: Urticaria, angioedema, and other skin disorders from the 2022 American College of Allergy, Asthma, and Immunology Annual Literature Review. | Ann Allergy Asthma Immunol | 2023 |
| 34287942 | Long-term prevention of hereditary angioedema attacks with lanadelumab: The HELP OLE Study. | Allergy | 2022 |
| 37780104 | Validation of a suspicion index to identify patients at risk for hereditary angioedema. | J Allergy Clin Immunol Glob | 2022 |
| 35831891 | Considerations in the management of hereditary angioedema due to C1-INH deficiency in women of childbearing age. | Allergy Asthma Clin Immunol | 2022 |
| 35497649 | The international WAO/EAACI guideline for the management of hereditary angioedema - The 2021 revision and update. | World Allergy Organ J | 2022 |
| 35820771 | Shared decision-making in the management of hereditary angioedema: An analysis of patient and physician perspectives. | Allergy Asthma Proc | 2022 |
| 36481049 | Differentiating histaminergic and nonhistaminergic angioedema with or without urticaria. | J Allergy Clin Immunol | 2022 |
| 35960533 | Consider Hereditary Angioedema in the Differential Diagnosis for Unexplained Recurring Abdominal Pain. | J Clin Gastroenterol | 2022 |
| 36057583 | Correction: Considerations in the management of hereditary angioedema due to C1-INH deficiency in women of childbearing age. | Allergy Asthma Clin Immunol | 2022 |
| 35294812 | Inhibition of Prekallikrein for Hereditary Angioedema. | N Engl J Med | 2022 |
| 34628006 | Optimization of care for patients with hereditary angioedema living in rural areas. | Ann Allergy Asthma Immunol | 2022 |
| 33349293 | Androgen use in hereditary angioedema: A critical appraisal and approaches to transitioning from androgens to other therapies. | Allergy Asthma Proc | 2021 |
| 33875020 | Assessment and management of disease burden and quality of life in patients with hereditary angioedema: a consensus report. | Allergy Asthma Clin Immunol | 2021 |
| 34871158 | COVID-19 and hereditary angioedema: Incidence, outcomes, and mechanistic implications. | Allergy Asthma Proc | 2021 |
| 33980329 | Physician and patient perspectives on the management of hereditary angioedema: a survey on treatment burden and needs. | Allergy Asthma Proc | 2021 |
| 33980328 | Caregivers' role in managing hereditary angioedema and perceptions of treatment-related burden. | Allergy Asthma Proc | 2021 |
| 33980327 | Patient perspectives on the treatment burden of injectable medication for hereditary angioedema. | Allergy Asthma Proc | 2021 |
| 33980326 | Insights into the treatment burden of hereditary angioedema in the evolving treatment landscape. | Allergy Asthma Proc | 2021 |
| 34166549 | Effectiveness of lanadelumab for preventing hereditary angioedema attacks: Subgroup analyses from the HELP study. | Clin Exp Allergy | 2021 |
| 34112474 | The Road to Better Urticaria and Angioedema Management. | J Allergy Clin Immunol Pract | 2021 |
| 34048855 | Consensus on treatment goals in hereditary angioedema: AÂ global Delphi initiative. | J Allergy Clin Immunol | 2021 |
| 33258114 | Impact of lanadelumab on health-related quality of life in patients with hereditary angioedema in the HELP study. | Allergy | 2021 |
| 33098856 | Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: AÂ randomized, double-blind, placebo-controlled phase 3 trial. | J Allergy Clin Immunol | 2021 |
| 33122123 | Current medical management of hereditary angioedema: Follow-up survey of US physicians. | Ann Allergy Asthma Immunol | 2021 |
| 32251736 | Experience with Intravenous Plasma-Derived C1-Inhibitor in Pregnant Women with Hereditary Angioedema: A Systematic Literature Review. | J Allergy Clin Immunol Pract | 2020 |
| 32042283 | Long-term efficacy and safety of subcutaneous C1-inhibitor in women with hereditary angioedema: subgroup analysis from an open-label extension of a phase 3 trial. | Allergy Asthma Clin Immunol | 2020 |
| 33109329 | Hereditary angioedema and shared decision making. | Allergy Asthma Proc | 2020 |
| 33109316 | A roadmap for optimal care of the patient with hereditary angioedema. | Allergy Asthma Proc | 2020 |
| 32248571 | Definition, aims, and implementation of GA<sup>2</sup> LEN/HAEi Angioedema Centers of Reference and Excellence. | Allergy | 2020 |
| 32445670 | Long-term safety and efficacy of subcutaneous C1-inhibitor in older patients with hereditary angioedema. | Ann Allergy Asthma Immunol | 2020 |
| 32399057 | Correction to: The International/Canadian Hereditary Angioedema Guideline. | Allergy Asthma Clin Immunol | 2020 |
| 32534150 | Association Between Self-Reported Dental Hygiene Practices and Dental Procedure-Related Recurrent Angioedema Attacks in HAE Subjects: A Multicenter Survey. | J Allergy Clin Immunol Pract | 2020 |
| 32452549 | Lanadelumab demonstrates rapid and sustained prevention of hereditary angioedema attacks. | Allergy | 2020 |
| 30660873 | Treatment effect of switching from intravenous to subcutaneous C1-inhibitor for prevention of hereditary angioedema attacks: COMPACT subgroup findings. | J Allergy Clin Immunol Pract | 2019 |
| 31788005 | The International/Canadian Hereditary Angioedema Guideline. | Allergy Asthma Clin Immunol | 2019 |
| 29909591 | Update on the Use of C1-Esterase Inhibitor Replacement Therapy in the Acute and Prophylactic Treatment of Hereditary Angioedema. | Clin Rev Allergy Immunol | 2019 |
| 31485239 | Subcutaneous C1 inhibitor for prevention of attacks of hereditary angioedema: additional outcomes and subgroup analysis of a placebo-controlled randomized study. | Allergy Asthma Clin Immunol | 2019 |
| 30772477 | Long-Term Outcomes with Subcutaneous C1-Inhibitor Replacement Therapy for Prevention of Hereditary Angioedema Attacks. | J Allergy Clin Immunol Pract | 2019 |